$3.55 Million in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter
Wall Street brokerages predict that Dynavax Technologies Co. (NASDAQ:DVAX) will announce sales of $3.55 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $3.00 million and the highest is $4.10 million. Dynavax Technologies reported sales of $50,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 7,000%. The company is scheduled to announce its next quarterly earnings report on Friday, November 2nd.
According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $11.62 million for the current fiscal year, with estimates ranging from $7.96 million to $15.27 million. For the next financial year, analysts expect that the company will post sales of $93.41 million, with estimates ranging from $88.23 million to $98.58 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.88 million. Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. Dynavax Technologies’s revenue for the quarter was up 1094.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.41) earnings per share.
Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can grew its stake in Dynavax Technologies by 365.4% in the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,943 shares during the period. Chicago Capital LLC grew its stake in Dynavax Technologies by 48.3% in the second quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock valued at $19,735,000 after acquiring an additional 421,446 shares during the period. Creative Planning grew its stake in Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after acquiring an additional 5,857 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in Dynavax Technologies in the first quarter valued at approximately $200,000. Finally, Tiverton Asset Management LLC acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $184,000. 82.02% of the stock is owned by hedge funds and other institutional investors.
Dynavax Technologies stock traded up $0.50 during trading hours on Friday, hitting $12.90. The stock had a trading volume of 17,771 shares, compared to its average volume of 831,618. The company has a current ratio of 8.87, a quick ratio of 8.67 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $751.39 million, a PE ratio of -7.38 and a beta of 0.24. Dynavax Technologies has a one year low of $11.35 and a one year high of $24.45.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
See Also: What is the S&P 500 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.